Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Glucagon (GlucaGen) peptide icon, one bubble per amino acidGlucagon (GlucaGen)29 residuesHSQGTFTSDYSKYLDSRRAQDFVQWLMNTEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Glucagon (GlucaGen)

MetabolicFDA Approved
8-18 minutes half-life·Injection/Nasal

Also known as: GlucaGen, Gvoke, Baqsimi

Every insulin-dependent diabetic carries a ticking clock. When blood sugar crashes below consciousness, glucagon is the 29-amino-acid peptide hormone that reverses it, typically within 10 to 15 minutes. Three FDA-approved formulations exist: a traditional reconstitution kit (GlucaGen), a prefilled autoinjector (Gvoke), and a needle-free nasal powder (Baqsimi). The catch is that glucagon only works if the liver still has glycogen to break down. Prolonged fasting, heavy alcohol use, or adrenal insufficiency can deplete those stores entirely. Type 1 and Type 2 diabetics on insulin or sulfonylureas keep a kit on hand as standard emergency preparedness.

What Is Glucagon (GlucaGen)?

Fewer than 50% of caregivers can correctly reconstitute a traditional glucagon emergency kit under simulated stress. That single statistic reshaped the entire product category and drove the development of two newer formulations.

Glucagon (CAS 16941-32-5) is a 29-amino-acid peptide hormone produced by pancreatic alpha cells. It is the primary counter-regulatory hormone to insulin. When blood glucose drops to dangerous levels, glucagon binds the glucagon receptor (GCGR) on hepatocytes, triggering a cAMP/protein kinase A cascade that breaks stored glycogen into glucose. Blood sugar typically rises 30 to 100 mg/dL within 10 to 20 minutes of parenteral administration.

Three FDA-approved formulations exist today. The traditional GlucaGen kit (Novo Nordisk) requires mixing lyophilized powder with a diluent syringe. Gvoke (Xeris Pharmaceuticals) ships as a room-temperature-stable prefilled autoinjector; no mixing required. Baqsimi (Eli Lilly, approved 2019) is a 3 mg intranasal powder that requires no injection at all. Clinical trials confirmed comparable blood sugar recovery across all three formats.

Real-world use is narrow and well-defined. Glucagon is strictly an emergency rescue medication for severe hypoglycemia in patients who can't swallow oral carbohydrates. It also carries an FDA indication as a diagnostic aid for GI radiologic examinations. No off-label wellness or optimization community exists. The diabetes community on Reddit and patient forums tracks this peptide closely, and consensus aligns with the FDA label almost exactly.

How Glucagon (GlucaGen) Works

Glucagon locks onto the glucagon receptor (GCGR), a class B G protein-coupled receptor sitting on the surface of liver cells. That binding event kicks off a specific intracellular cascade.

The receptor activates its stimulatory G-alpha subunit (Gs), which flips on adenylyl cyclase. Adenylyl cyclase converts ATP into cyclic adenosine monophosphate (cAMP). Rising cAMP levels inside the hepatocyte activate protein kinase A (PKA). Two things happen from there.

First, PKA phosphorylates phosphorylase kinase, converting it from inactive (b) to active (a) form. Active phosphorylase kinase then phosphorylates glycogen phosphorylase. That enzyme starts cleaving glucose-1-phosphate units off glycogen chains. This process, glycogenolysis, is what physically dumps glucose into the bloodstream. PKA also shuts down glycogen synthase so the liver stops storing glucose and starts releasing it.

Second, PKA phosphorylates the transcription factor CREB (cAMP response element-binding protein). CREB turns up expression of gluconeogenic enzymes, specifically phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). PKA simultaneously dials down glycolysis by reducing pyruvate kinase and phosphofructokinase-2 activity. The net result: blood glucose rises 30 to 100 mg/dL within 10 to 20 minutes of injection [1].

Glucagon (GlucaGen) Benefits

  • Glucagon benefits center on rapid, reliable rescue from life-threatening hypoglycemia.
  • Blood glucose starts climbing within 5 to 10 minutes of a 1 mg injection. Most patients regain consciousness by 10 to 15 minutes (GlucaGen FDA Prescribing Information, NDA 020918s056).
  • Gvoke and Baqsimi require zero reconstitution. In simulated emergency testing, fewer than half of caregivers could correctly mix the traditional kit; the newer formats removed that failure point entirely.
  • Baqsimi delivers 3 mg intranasally with no needle. Clinical trials confirmed glycemic recovery comparable to intramuscular injection, with Tmax around 15 minutes versus 13 minutes for IM (Baqsimi FDA PI, NDA 210134).
  • Decades of FDA-approved clinical use back the safety profile. Over 4,200 PubMed-indexed studies exist for glucagon, making it one of the most thoroughly characterized peptide hormones in medicine.
  • The diagnostic indication is often overlooked. Glucagon temporarily inhibits GI motility during radiologic examinations. A dose of 0.25 to 0.5 mg IV produces relaxation onset in about 1 minute lasting 9 to 17 minutes.
  • Most insurance plans cover glucagon with minimal copay. Eli Lilly offers a $25/fill savings card for Baqsimi (max $1,800/year). Novo Nordisk runs a patient assistance program providing the generic kit free for eligible patients.

Glucagon (GlucaGen): Science vs Community Consensus

Aligned
Scientific Evidence
Strong
Based on 4 key studies·FDA-approved

FDA-approved for severe hypoglycemia rescue in diabetics; 29-aa peptide hormone with well-characterized glycogenolysis mechanism; three approved formulations (traditional kit, Gvoke autoinjector, Baqsimi intranasal)

Dosing studied: 0.5 mg SC/IM for pediatric patients <25 kg; 1 mg SC/IM/IV for adults and children ≥25 kg; 3 mg intranasal (Baqsimi, ages ≥4 yr); repeat once at 15 min if no response
Read the evidence (key study, limitations)
Key Study

GlucaGen FDA Prescribing Information 2021 (NDA 020918s056); Baqsimi FDA Prescribing Information 2019 (NDA 210134); Gvoke FDA PI 2019 (NDA 210134)

Limitations

Efficacy requires intact hepatic glycogen stores: fails in prolonged fasting, heavy alcohol use, adrenal insufficiency, or hepatic glycogen depletion; IV dextrose is the only alternative in those cases; not appropriate for any non-emergency chronic use

Community Experience
Strong
3.5/5
Based on aggregated from r/diabetes, r/diabetes_t1, r/NovaLog (high mention volume)

Universally considered an essential emergency medication for insulin-dependent diabetics; strong consensus to always have a kit on hand; Gvoke preferred by injectors; Baqsimi preferred for caregiver-administered needle-free scenarios

Community dosing: 1 mg adult standard dose; Gvoke (0.5 mg or 1 mg prefilled) or Baqsimi (3 mg) strongly preferred over traditional reconstitution kits
Read the reports (what users report 5, common issues 5)
What users report (5)
  • Restores consciousness within 10-15 minutes in most patients
  • Gvoke and Baqsimi require no reconstitution: usable by panicked caregivers
  • Baqsimi requires no injection: viable option when caregivers cannot administer injections
  • Room-temperature stable for all modern formulations
  • Covered by most insurance with minimal or no copay
Common issues (5)
  • Baqsimi causes intense nasal burning and irritation in many users (described as "liquid cayenne pepper" in reviews)
  • High out-of-pocket cost without insurance: $401-560 (Baqsimi), ~$399 (Gvoke)
  • Traditional kit requires multi-step reconstitution that fewer than 50% of caregivers can perform correctly under simulated emergency conditions
  • Effect wears off within 60 minutes: rebound hypoglycemia common if oral carbs not given immediately after recovery
  • Fails completely if hepatic glycogen is depleted: community frequently does not know this limitation
Science & Community Aligned

Science and community use case are identical: emergency hypoglycemia rescue only. Community consensus tracks FDA label dosing precisely. No off-label wellness or optimization use exists in the community.

Glucagon (GlucaGen) Dosage Guide

FDA LabelGlucaGen (glucagon) FDA Prescribing Information (2021)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner1 mgSingle dose; may repeat once after 15 min if no response
Moderate1 mgSingle dose; may repeat once after 15 min if no response
Aggressive1 mgSingle dose; may repeat once after 15 min if no response
Note:

Glucagon isn't something you'll reconstitute at your leisure. If you're using the traditional kit, you're doing it while someone is unconscious and you're panicking.

Here's the reconstitution math for the traditional 1 mg kit. The vial contains 1 mg lyophilized glucagon. Inject the full 1 mL of accompanying diluent into the vial. Swirl gently until dissolved (clear, colorless solution). The resulting concentration is 1 mg/mL. For an adult dose (1 mg), draw the full 1 mL, which equals 100 units on a U-100 insulin syringe. For a pediatric dose under 25 kg, draw 0.5 mL (50 units on that same syringe).

Use immediately after reconstitution. Do not store reconstituted glucagon. Discard any unused portion.

For a family member who might need to use it under pressure, consider Gvoke or Baqsimi instead. The traditional kit's multi-step reconstitution fails under emergency conditions more often than most people realize. Store at room temperature (20 to 25 degrees C). Don't refrigerate. Don't freeze. Check your expiration date at every diabetes appointment.

Cycling

Emergency use only: glucagon is not cycled. Administered as a single rescue dose during episodes of severe hypoglycemia. No ongoing or prophylactic dosing protocol exists.

Calculate your Glucagon (GlucaGen) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Glucagon (GlucaGen) Protocols by Goal

beginnerFDA LabelSingle-dose emergency use; not a scheduled treatment
Emergency rescue
Wk Single episode
1 mg · Once; repeat 1 mg at 15 min if no response · SC or IM (preferred); IV acceptable

Expected: Blood glucose begins rising within 5-10 min; most patients regain consciousness within 10-15 min; peak effect ~15-30 min

Monitor: Monitor blood glucose at 15 min; monitor heart rate and blood pressure if patient is on beta-blockers (exaggerated cardiovascular response possible)

How to Use Glucagon (GlucaGen)

  1. 1
    Step 1

    Traditional GlucaGen/Glucagon Emergency Kit: Remove the flip-off seal from the vial. Inject the full contents of the diluent syringe (1 mL) into the vial of lyophilized powder. Swirl gently until completely dissolved. Solution should be clear and colorless. If cloudy or particulate, discard it.

  2. 2
    Draw the dose

    Adults and children over 25 kg: draw 1 mL (100 units on a U-100 syringe) for the full 1 mg dose. Children under 25 kg: draw 0.5 mL (50 units) for the 0.5 mg dose.

  3. 3
    Step 3

    Inject subcutaneously or intramuscularly into the upper arm, thigh, or buttock. A 25 to 27 gauge needle works for intramuscular. Standard 29 to 31 gauge insulin syringe is fine for subcutaneous. IV is acceptable in clinical settings but not practical for home emergencies.

  4. 4
    Step 4

    Gvoke autoinjector or prefilled syringe: No reconstitution needed. Remove cap. Press against outer thigh or abdomen. Activate. Delivers 0.5 mg or 1 mg based on weight. Room-temperature stable.

  5. 5
    Baqsimi intranasal: Insert the device tip into one nostril

    Press the plunger firmly. That delivers the full 3 mg dose. No inhalation required. Do not reuse the device.

  6. 6
    Step 6

    After any formulation: Position the patient on their side to prevent aspiration if vomiting occurs. Once consciousness returns, give 15 to 20g fast-acting oral carbohydrates immediately. Call emergency services regardless of response.

  7. 7
    If no response at 15 minutes, repeat the dose once

    Same formulation, same amount. For Baqsimi, use a new device. IV dextrose is the only alternative if glucagon fails, which points to depleted glycogen stores.

Alternative Routes

Subcutaneous (SC)

No dose adjustment vs IM; Tmax ~20 min vs ~13 min IM

Upper arm, thigh, or buttock. Half-life ~35-45 min (apparent, reflecting prolonged absorption).

Intramuscular (IM)

Same dose as SC (0.5 mg or 1 mg); Tmax ~13 min

FDA GlucaGen label apparent t½ = 45 min IM (prolonged absorption from injection site). Gvoke autoinjector is designed for SC use but IM is also acceptable per label.

Intravenous (IV)

Same dose (1 mg adult); Tmax immediate; t½ 8-18 min (shortest)

Rapid IV injection (>1 mg) increases vomiting risk significantly. Standard emergency department route. Not practical for home emergency use without IV access.

Intranasal (Baqsimi)

3 mg IN = 1 mg IM/SC for glycemic response (higher dose compensates for lower bioavailability via nasal route); Tmax ~15 min

Comparable glycemic outcomes to IM/SC in clinical trials. Higher rate of nasal side effects (burning, congestion, watery eyes). No inhalation needed: passive delivery by plunger.

Glucagon (GlucaGen) Stacking Protocols

Works With

Avoid

Indomethacin (and NSAIDs)

May blunt or completely abolish the hyperglycemic effect of glucagon; mechanism involves inhibition of hepatic cAMP-mediated response

Do not combine
Beta-blockers (propranolol, metoprolol, etc.)

Exaggerated and potentially prolonged increases in blood pressure and heart rate; glycemic response is preserved but cardiovascular response may be dangerous in patients with coronary artery disease

Warfarin (and anticoagulants)

Glucagon potentiates the anticoagulant effect of warfarin; may increase bleeding risk; monitor INR if glucagon is used in a warfarin patient

Estimated Cost

Brand Price
Baqsimi 3 mg intranasal: ~$401-560 retail; ~$280-560 typical US cash price with a discount card; $25/fill savings card (max $1,800/yr). Gvoke HypoPen autoinjector: ~$399 retail; ~$348 typical US cash price with a discount card; $25/month copay card available.
Generic / Research
Glucagon Emergency Kit (generic): ~$309-517 retail; ~$143-279 typical US cash price with a discount card; free via Novo Nordisk Patient Assistance Program for eligible patients

Pricing updated 2026-04-09

Glucagon (GlucaGen) Side Effects

Nausea hits up to 35% of patients [2]. That makes it the most frequently reported adverse effect. Vomiting usually follows, especially with rapid intravenous doses exceeding 1 mg. Position the patient on their side before administration to prevent aspiration. This isn't optional guidance; it's a real risk when someone is unconscious and about to receive a medication that commonly triggers vomiting.

Headache is the other common complaint. Transient spikes in blood pressure and heart rate occur, and this is where the beta-blocker interaction gets dangerous. Patients taking propranolol, metoprolol, or similar drugs can experience exaggerated and prolonged cardiovascular responses. In patients with known coronary artery disease on beta-blockers, the interaction can be clinically serious. Monitor cardiovascular status in those patients.

Baqsimi's intranasal route carries its own side effect profile. Users describe the nasal burning as intense. One recurring description in patient reviews across WebMD (n=24 Baqsimi reviews) is "liquid cayenne pepper." Watery eyes, nasal congestion, and upper respiratory tract irritation are reported frequently with the nasal formulation.

Injection site reactions (redness, swelling) show up with subcutaneous and intramuscular formulations. These are generally short-lived.

The rare but serious risks need their own weight. Generalized allergic reactions and anaphylactic shock (with hypotension and breathing difficulty) are in the literature. They're uncommon, but they exist. Rebound hypoglycemia is the more practically dangerous concern. The glucagon effect wears off within 30 to 60 minutes. If oral carbohydrates aren't given once the patient can swallow, blood sugar will crash again. Community reports on r/diabetes frequently describe this pattern: "thought they were fine and then crashed again."

Hypokalemia has been observed in overdose scenarios. The biggest limitation isn't a side effect per se, but a failure mode. Glucagon cannot raise blood sugar if hepatic glycogen stores are depleted. Prolonged fasting, heavy alcohol use, adrenal insufficiency, or chronic hypoglycemia can leave nothing for glucagon to mobilize. The FDA label says to call emergency services regardless of response.

Contraindications: pheochromocytoma (risk of catecholamine-driven hypertensive crisis), insulinoma (paradoxical hypoglycemia from stimulated insulin release), glucagonoma (exaggerated hyperglycemia), and hypersensitivity to glucagon or excipients including lactose monohydrate. Pregnancy is FDA Category B with no adequate human studies. Whether glucagon passes into breast milk is unknown.

Common Issues & Solutions

No blood glucose response at 15 min: most likely cause is depleted hepatic glycogen stores (prolonged fasting, alcohol intoxication, adrenal insufficiency, liver disease): glucagon cannot mobilize glucose that is not there; IV dextrose is the only alternative; call emergency services immediately

Patient vomits before regaining consciousness: position on side before administering glucagon to prevent aspiration; this is expected: nausea/vomiting occur in up to 35% of cases

Blood glucose recovers but drops again within 30-60 min: rebound hypoglycemia from glucagon effect waning: oral carbohydrates (15-20g fast-acting) must be given as soon as patient can swallow; do not skip this step

Caregiver cannot operate traditional reconstitution kit under pressure: switch prescription to Gvoke HypoPen or Baqsimi; fewer than 50% of caregivers successfully complete traditional kit reconstitution in simulated emergencies

Exaggerated hypertension or tachycardia after administration: patient is likely on beta-blockers; the cardiovascular response is amplified and prolonged; effect is transient but monitor closely and seek medical evaluation

Ask AI about this page

Ask AI for a second opinion on Glucagon (GlucaGen) dosing and side effects

Contraindications

  • Known pheochromocytoma: glucagon may stimulate catecholamine release causing hypertensive crisis
  • Known insulinoma: may cause paradoxical hypoglycemia via stimulated insulin release
  • Known glucagonoma: risk of exaggerated hyperglycemic response
  • Hypersensitivity to glucagon or any excipient (including lactose monohydrate in some formulations)
  • Pregnancy: FDA Category B; no adequate human studies; use only if clearly needed
  • Breastfeeding: unknown whether glucagon is excreted in human milk; use with caution
  • Adrenal insufficiency (relative), glucagon depends on intact hepatic glycogen stores; adrenal insufficiency depletes glycogen, reducing or eliminating efficacy

Drug Interactions

  • Insulin: directly antagonizes glucagon effects on blood glucose
  • Beta-blockers: may cause exaggerated transient increases in blood pressure and heart rate
  • Indomethacin: may blunt or abolish the hyperglycemic effect of glucagon
  • Warfarin: glucagon may potentiate the anticoagulant effect, increasing bleeding risk
  • Warfarin (and anticoagulants)
  • Glucagon potentiates the anticoagulant effect of warfarin; may increase bleeding risk; monitor INR if glucagon is used in a warfarin patient

Product Quality

Recommended Monitoring

TestWhenTarget
Blood glucoseAt 15 min post-administration; again at 30-60 minBG ≥70 mg/dL sustained; if still <70 mg/dL at 15 min, repeat dose and call 911
Blood pressure and heart rateDuring and after administration in patients on beta-blockers or with known CADNot listed
Blood glucose

Confirm glycemic response; detect failure (glycogen depletion) or rebound hypoglycemia

Blood pressure and heart rate

Glucagon + beta-blockers causes exaggerated and prolonged cardiovascular response; risk of hypertensive episode or arrhythmia in high-risk patients

Glucagon (GlucaGen) Before and After

0-5 minutes

Glucagon absorbed from injection or nasal mucosa; hepatic signaling cascade initiated

5-10 minutes

Blood glucose begins to rise as glycogenolysis mobilizes hepatic glucose stores

10-15 minutes

Most patients regain consciousness; blood glucose typically elevated 30-100 mg/dL above baseline

15-30 minutes

Peak plasma glucose reached; patient should be given oral carbohydrates to sustain recovery

30-60 minutes

Glucagon effect waning; risk of rebound hypoglycemia if glycogen stores are depleted

What to Expect

0 to 5 minutes: Glucagon is absorbing from the injection site or nasal mucosa. The GCGR binding event initiates the cAMP cascade in hepatocytes. Glycogenolysis starts at the molecular level. The patient is still unconscious or unresponsive. Nothing visible is happening yet. Caregivers are typically calling 911 during this window. Sweating from the hypoglycemia is ongoing.

5 to 10 minutes: Hepatic glucose output is increasing. Blood glucose climbs at roughly 1 to 2 mg/dL per minute, depending on how much glycogen the liver has stored. Some patients show early stirring. Most are still unconscious. Caregivers sometimes report seeing color return to the patient's face. Nausea may begin as blood glucose rises.

10 to 15 minutes: This is when most patients wake up. Peak plasma glucagon concentration hits around 13 minutes after intramuscular injection [1]. Blood glucose is typically 30 to 100 mg/dL above the pre-treatment low point. The community describes this recovery as "dramatic." Nausea and vomiting affect about 35% of patients. Headache is common. Baqsimi users report nasal burning.

15 to 30 minutes: Peak blood glucose is reached. The patient can swallow now, and oral carbohydrates need to go in immediately. Juice, glucose tablets, anything fast-acting. The patient is alert but fatigued and disoriented. Paramedics are usually on scene. Blood pressure and heart rate may be raised, especially in patients on beta-blockers.

30 to 60 minutes: Glucagon's effect is fading. Plasma concentration is dropping toward baseline. The liver's glycogen stores were partially depleted by the glycogenolysis that saved the patient's life. Without those oral carbohydrates, blood glucose will fall again. Rebound hypoglycemia catches people off guard. Community reports on r/diabetes repeat the same pattern: "thought they were fine and then crashed again."

Detailed Timeline: Science vs Community

0-5 minutes
Science

Glucagon absorbed from injection site or nasal mucosa; GCGR binding initiates cAMP cascade in hepatocytes; glycogenolysis begins

Community

Patient is still unconscious or unresponsive; no visible change yet; caregivers typically calling 911 during this window

5-10 minutes
Science

Hepatic glucose output increases; blood glucose begins rising at ~1-2 mg/dL per minute depending on glycogen store status

Community

Some patients show early stirring; most still unconscious; some users report seeing color return to patient's face

10-15 minutes
Science

Peak plasma glucagon ~13 min (IM); blood glucose typically elevated 30-100 mg/dL above pre-treatment nadir; most patients regain consciousness

Community

Strong community consensus: most patients are awake and confused by 10-15 min; community frequently notes the "dramatic" recovery

15-30 minutes
Science

Peak blood glucose; patient able to swallow; oral carbohydrates should be given immediately to sustain recovery

Community

Patient alert but typically fatigued and disoriented; oral glucose or juice given; paramedics usually arriving

30-60 minutes
Science

Glucagon plasma concentration returning to baseline; hepatic glycogen stores depleted by the glucagonolysis; without oral carbs, blood glucose will fall again

Community

Community frequently reports surprise second hypoglycemia episode if oral carbs were not given; "thought they were fine and then crashed again" is a common account

Pharmacokinetics

Half-Life
26min
Bioavailability
IM/SC: ~100% relative to IV for glucose-raising effect; Intranasal: comparable glycemic response
Tmax
IM: ~13 min; SC: ~20 min; Intranasal: ~15 min
Data Confidence
high

Source: Cersosimo et al., Diabetes Care 1985; PMID 3971846: IV t½ 8-18 min; IM ~26 min; SC/IN ~35-45 min

Pharmacokinetics: Active Dose Over Time

t½ = 8-18 minutes (IV), ~26 minutes (IM), ~35-45 minutes (SC/intranasal)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
29
Sequence
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Glucagon (GlucaGen)

  • Type 1 diabetes patients at risk of severe hypoglycemia
  • Type 2 diabetes patients on insulin or sulfonylureas
  • Pediatric diabetes patients
  • Caregivers and family members of insulin-dependent diabetics
  • Emergency medical services and first responders

Related Peptides

What Changed for Glucagon (GlucaGen)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 8, 20266 Citations

References

  1. [1]Pharmacokinetics and Bioavailability of Injected Glucagon: Differences Between Intramuscular, Subcutaneous, and Intravenous Administration (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]FDA NDA 020918
  4. [4]FDA NDA 210134

Related Tools

Storage & Stability

Before Reconstitution
Up to 24 months at controlled room temperature in original packaging; do not freeze
After Reconstitution
Use immediately after reconstitution; discard any unused portion
Temperature
20-25°C (68-77°F); do not refrigerate or freeze

Frequently Asked Questions

Glucagon works by breaking down stored liver glycogen into glucose. If your glycogen stores are depleted; from prolonged fasting, heavy alcohol use, or adrenal insufficiency; there's nothing to break down and blood sugar won't rise. That's why the label says to always call emergency services regardless.

All three deliver 1 mg glucagon for adults but differ in how stressful they are to use in a crisis. The traditional kit requires mixing powder with diluent (nerve-wracking in an emergency). Gvoke is a ready-to-use prefilled syringe. No mixing needed. Baqsimi is an intranasal powder. No injection at all. Clinical trials showed comparable blood sugar recovery for all three.

Studies show expired kits retain efficacy for 12-20 months past the label date when stored properly. Manufacturers still say replace at expiration, and that's the right call for an emergency medication. But in a life-threatening situation with nothing else available? Use it.

Yes, the blood sugar effect still works through the liver mechanism. But expect an exaggerated and potentially prolonged spike in blood pressure and heart rate. In patients with known coronary artery disease on beta-blockers, this interaction can be clinically significant. Monitor cardiovascular status.

Yes, it's used in emergency toxicology for sulfonylurea-induced hypoglycemia in both diabetics and non-diabetics. One caveat: in sulfonylurea overdose, glucagon can paradoxically stimulate further insulin release, so the effect may be only temporary. IV dextrose remains the definitive treatment in overdose scenarios.